Net Loss: Nuvectis Pharma Inc (NASDAQ:NVCT) reported a net loss of $22.3 million for FY 2023, an increase from $19.1 million in FY 2022. Research and Development Expenses: R&D expenses rose to $15.4 ...
Source LinkNet Loss: Nuvectis Pharma Inc (NASDAQ:NVCT) reported a net loss of $22.3 million for FY 2023, an increase from $19.1 million in FY 2022. Research and Development Expenses: R&D expenses rose to $15.4 ...
Source Link
Comments